CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months

Abstract excerpt

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is the most common subtype of ALL in adults and is historically associated with worse outcomes. While the landscape has significantly improved with the introduction of tyrosine kinase inhibitors (TKIs), relapse remains a significant clinical challenge [ 1 ]. Assessment of measurable residual disease (MRD) by reverse transcriptase polymerase...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CAR-T cell therapy research